LL-37 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is researched primarily for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement. The human body's own antibiotic peptide with multiple killing mechanisms that prevent bacterial resistance development — unlike conventional antibiotics, bacteria cannot easily evolve resistance to membrane disruption. It belongs to the Antimicrobial peptide, host defense peptide category of compounds.
What Is LL-37?
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide. Endogenous human antimicrobial peptide; the only human member of the cathelicidin family; produced by neutrophils, macrophages, and epithelial cells.
The human body's own antibiotic peptide with multiple killing mechanisms that prevent bacterial resistance development — unlike conventional antibiotics, bacteria cannot easily evolve resistance to membrane disruption. It has attracted significant research interest for its potential effects on broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.
How Does LL-37 Produce These Benefits?
Kills pathogens through multiple mechanisms: converts from random coil to α-helix structure, burrows into bacterial membranes causing permeabilization (carpet model), generates oxidative stress in bacterial cells, and disrupts biofilms and viral envelopes. Also immunomodulatory — activates chemokine receptors and enhances inflammatory response. Effective against 38+ bacteria, 16 fungi, and 16 viruses.
This multi-pathway activity is why LL-37 shows potential across several different applications rather than being limited to a single use case.
Can LL-37 Help With Broad-Spectrum Antimicrobial Activity?
Research suggests LL-37 may support broad-spectrum antimicrobial activity through its antimicrobial peptide, host defense peptide activity. Achieves 3+ log reduction of S. aureus biofilms within 5 minutes at therapeutic concentrations. A derivative (omiganan/ropocamptide) advanced to late-stage clinical trials for catheter-site infections. Multiple antimicrobial peptides in this class entering human trials.
Protocols targeting broad-spectrum antimicrobial activity typically use 100-500 mcg (topical/local application) administered topical or local application as needed for acute use as needed.
Can LL-37 Help With Biofilm Disruption?
Research suggests LL-37 may support biofilm disruption through its antimicrobial peptide, host defense peptide activity. Achieves 3+ log reduction of S. aureus biofilms within 5 minutes at therapeutic concentrations. A derivative (omiganan/ropocamptide) advanced to late-stage clinical trials for catheter-site infections. Multiple antimicrobial peptides in this class entering human trials.
Protocols targeting biofilm disruption typically use 100-500 mcg (topical/local application) administered topical or local application as needed for acute use as needed.
Can LL-37 Help With Wound Healing Acceleration?
Research suggests LL-37 may support wound healing acceleration through its antimicrobial peptide, host defense peptide activity. Achieves 3+ log reduction of S. aureus biofilms within 5 minutes at therapeutic concentrations. A derivative (omiganan/ropocamptide) advanced to late-stage clinical trials for catheter-site infections. Multiple antimicrobial peptides in this class entering human trials.
Protocols targeting wound healing acceleration typically use 100-500 mcg (topical/local application) administered topical or local application as needed for acute use as needed.
Can LL-37 Help With Immune Enhancement?
Research suggests LL-37 may support immune enhancement through its antimicrobial peptide, host defense peptide activity. Achieves 3+ log reduction of S. aureus biofilms within 5 minutes at therapeutic concentrations. A derivative (omiganan/ropocamptide) advanced to late-stage clinical trials for catheter-site infections. Multiple antimicrobial peptides in this class entering human trials.
Protocols targeting immune enhancement typically use 100-500 mcg (topical/local application) administered topical or local application as needed for acute use as needed.
Can Stacking Enhance LL-37 Benefits?
Pairs with BPC-157 for wound healing — LL-37 handles antimicrobial defense while BPC-157 promotes tissue repair.
See our LL-37 stacking guide for detailed combination protocols.
What Is the Bottom Line on LL-37 Benefits?
LL-37 is researched for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement. The evidence base includes: Achieves 3+ log reduction of S. aureus biofilms within 5 minutes at therapeutic concentrations. A derivative (omiganan/ropocamptide) advanced to late-stage clinical trials for catheter-site infections. Multiple antimicrobial peptides in this class entering human trials.
LL-37 is not fda-approved as therapeutic. research compound. derivatives in late-stage clinical trials. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
LL-37 : Benefits, Dosage, Side Effects & Research
Related Reading
- LL-37 Dosage Guide
- LL-37 Side Effects
- LL-37 Stacking Guide
- LL-37 Cycle Guide
- LL-37 Research
- BPC-157 Complete Guide
Calculate Your LL-37 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for LL-37.
Open Calculator →Research-Grade Sourcing
If you're going to research LL-37, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is LL-37?
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide. Endogenous human antimicrobial peptide; the only human member of the cathelicidin family; produced by neutrophils, macrophages, and epithelial cells. It is researched for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.
What is the recommended LL-37 dosage?
Common dosages: 100-500 mcg (topical/local application) administered topical or local application as needed via topical wound application, local injection, intranasal. Cycle length: acute use as needed. Half-life: rapidly degraded by proteases; major clinical limitation. Use our peptide calculator for exact reconstitution math.
What are the side effects of LL-37?
Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation.
Is LL-37 safe?
LL-37 has shown a preliminary safety profile in research. Not FDA-approved as therapeutic. Research compound. Derivatives in late-stage clinical trials. All research should follow appropriate safety protocols.